EdiGene develops genome editing technologies, including the LEAPER platform for in vivo RNA base editing and the MAGIC platform for allogeneic cell therapies, to address genetic diseases and cancer. Their high-throughput genome editing screening capabilities enable precise therapeutic interventions, enhancing treatment efficacy and patient outcomes.
Funding
$61.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LVFounders
Product
Problem
Many genetic diseases and cancers lack effective treatments due to the challenges of precisely targeting and modifying disease-causing genes within the body or in cells for therapeutic use. Current genome editing techniques often face limitations in delivery efficiency, specificity, and immunogenicity, hindering their clinical application.
Solution
EdiGene is developing advanced genome editing technologies for genetic diseases and cancer. Their LEAPER platform enables in vivo RNA base editing, offering a precise method for correcting genetic mutations directly within the patient's body. The MAGIC platform facilitates allogeneic cell therapies by enhancing immune compatibility, reducing the risk of rejection. EdiGene's high-throughput genome editing screening capabilities allow for the identification of optimal therapeutic targets and the development of highly specific and effective interventions. These platforms aim to improve treatment efficacy and patient outcomes by addressing the limitations of traditional gene therapies.
Target Audience
EdiGene's primary target audience includes patients suffering from genetic diseases and various forms of cancer, as well as pharmaceutical companies and research institutions seeking innovative gene editing solutions.
Features
- LEAPER (Leveraging endogenous adenosine deaminases for programmable editing on RNA) platform for in vivo RNA base editing
- MAGIC platform for generating immune-compatible allogeneic cell therapies
- High-throughput genome editing screening platform for target identification and validation
- Development of gene therapies using the LEAPER platform
- Development of cell therapies using the MAGIC platform
- Focus on both in vivo and ex vivo therapeutic approaches